Effect of CB-154 therapy on the glucose tolerance, IRI and GH response to glucose administration in acromegaly. 1978

R Demura, and H Yamaguchi, and H Demura, and K Shizume

Effects of CB-154 therapy on the glucose tolerance, IRI and GH responses to the oral glucose administration in 5 acromegalic patients with impaired glucose tolerance were examined. Glucose tolerance improved in all patients with a reduction in GH levels. Insulin secretion in response to the oral glucose administration was exaggerated in 3 patients, while it was supressed in 2 patients who had severely impaired glucose tolerance. After receiving CB-154 therapy, hyperresponsiveness of insulin observed in the 3 patients and a suppressed response in one patient were corrected to normal, while a low response in another stayed unchanged. This observation suggest that variable abnormalities in insulin secretion induced by the excess of GH improve with a decrease in plasma GH levels. However, the abnormal GH secretion in response to hyperglycemia persisted still after administration of CB-154 in spite of decreased basal plasma GH levels.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D007330 Insulin Antibodies Antibodies specific to INSULIN. Antibodies, Insulin
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001971 Bromocriptine A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion. 2-Bromoergocryptine,Bromocryptin,2-Bromo-alpha-ergocryptine,2-Bromo-alpha-ergokryptine,2-Bromoergocryptine Mesylate,2-Bromoergocryptine Methanesulfonate,2-Bromoergokryptine,Bromocriptin,Bromocriptine Mesylate,CB-154,Parlodel,2 Bromo alpha ergocryptine,2 Bromo alpha ergokryptine,2 Bromoergocryptine,2 Bromoergocryptine Mesylate,2 Bromoergocryptine Methanesulfonate,2 Bromoergokryptine,CB 154,CB154,Mesylate, 2-Bromoergocryptine,Mesylate, Bromocriptine,Methanesulfonate, 2-Bromoergocryptine
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000172 Acromegaly A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80) Inappropriate Growth Hormone Secretion Syndrome (Acromegaly),Somatotropin Hypersecretion Syndrome (Acromegaly),Inappropriate GH Secretion Syndrome (Acromegaly),Hypersecretion Syndrome, Somatotropin (Acromegaly),Hypersecretion Syndromes, Somatotropin (Acromegaly),Somatotropin Hypersecretion Syndromes (Acromegaly),Syndrome, Somatotropin Hypersecretion (Acromegaly),Syndromes, Somatotropin Hypersecretion (Acromegaly)

Related Publications

R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
R Demura, and H Yamaguchi, and H Demura, and K Shizume
December 1977, Horumon to rinsho. Clinical endocrinology,
Copied contents to your clipboard!